Shares of Alphatec Holdings surged +9.4% to $9.67 on September 11 after filings revealed that CEO Patrick Miles purchased 115,000 shares on the open market the day before, spending roughly $1.01 million at a weighted average of $8.81 per share. In the past three months, insiders bought 135,000 shares while selling only 6,050 — a sharp reversal for a stock that had seen heavy executive selling over the prior 18 months. The move comes as broader indexes lift on in-line inflation data, but the insider buy is the clear stock-specific catalyst.

  • The CEO Is Buying Near the Bottom, and That's Rare for Him. ATEC's 52-week range spans from $6.82 to $23.29 , meaning the stock is trading in the lower quarter of its yearly range. Over the past 18 months, insiders sold a net 6.58 million shares , largely through pre-planned programs tied to tax obligations. Miles choosing to voluntarily spend $1 million in the open market — not through an automatic plan — signals he believes the stock is meaningfully undervalued. When a CEO puts personal cash on the line, it tells the market he sees something the price doesn't reflect.

  • The Business Is Growing Faster Than the Stock Price Suggests. ATEC posted Q2 2026 revenue of $214 million, up 15% year-over-year, with surgical revenue climbing 17%.

Adjusted EBITDA hit $36 million, up 53% from the prior year, with margins expanding to 17%.

Full-year revenue guidance sits at approximately $882 million. Yet at $9.67, the stock is down more than 58% from its 52-week high — a disconnect between improving operations and a punished valuation.

  • The Q1 Earnings Miss Left Deep Scars. Q1 revenue of $192 million missed forecasts by roughly 2.8%, and the stock plunged over 32% after hours , driven by weakness in the company's imaging segment. Miles acknowledged the challenges and said the company is focused on improving that segment and increasing attachment rates for biologics products. The CEO's purchase can be read as a bet that the Q1 damage was an overreaction and that Q2's rebound validated the core surgical business.

  • Analysts Still See Major Upside, But the Market Doesn't Care — Yet. Wall Street price targets range from $12 to $24 over the next 12 months , implying at least 24% upside from today's price at the low end. The company carries a market cap of roughly $1.27 billion against trailing revenue approaching $800 million — barely 1.6x sales for a spine-surgery business still growing at a double-digit clip. The question now: will one CEO's conviction trade be enough to break the stock out of its post-Q1 slump, or will lingering doubts about profitability keep buyers on the sidelines?